Staff

Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer

Vancouver, British Columbia--(Newsfile Corp. - June 29, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased...

error: Content is protected !!